

Cipla Launches First-of-its-kind Sputum Inflammometry Lab

Housed at Mumbai's Breathefree Lung Wellness Center to advance airway inflammation testing capabilities in India

Mumbai, June 03rd, 2026: Cipla Limited (BSE: 500087; NSE: CIPLA; and hereafter referred to as "Cipla") today announced the launch of a first-of-its-kind Sputum Inflammometry Lab at the Breathefree Lung Wellness Center (BLWC) in Mumbai, marking the advancement of precision respiratory diagnostics and integrated respiratory care in the country.

The lab was inaugurated by Dr. Parameswaran Nair, globally recognised as one of the pioneers and leading experts in the field of Sputum Inflammometry. The inauguration took place in the presence of 15 eminent pulmonologists and respiratory experts from leading institutes across India.

Sputum inflammometry is an advanced diagnostic approach that assesses airway inflammation in patients with chronic respiratory conditions such as severe asthma, chronic obstructive pulmonary disease (COPD), and bronchiectasis. By analyzing inflammatory cells and biomarkers in sputum samples, it enables more accurate diagnosis, personalised treatment, and better disease monitoring. Integrated within the Breathefree Lung Wellness Center, the lab will also support clinician training, respiratory research, and scientific collaboration on sputum inflammometry in India.

Speaking on the occasion, Dr Jaideep Gogtay, Global Chief Medical Officer, Cipla Limited said, "Chronic respiratory diseases are increasingly complex and heterogeneous in nature, making accurate assessment of airway inflammation critical for optimal disease management. Sputum Inflammometry has transformed the understanding and management of airway diseases globally by enabling clinicians to identify specific inflammatory phenotypes and tailor therapy accordingly. This advanced capability can now play an important role in improving respiratory care and advancing clinical research in India."

The Breathefree Lung Wellness Center (BLWC) is Cipla's integrated, one-stop destination for advanced lung health diagnostics and care, combining cutting-edge technology, globally recognised protocols, and specialised clinical expertise to enable early and accurate detection of respiratory diseases. With the launch of the Sputum Inflammometry Lab, BLWC Mumbai further strengthens its capabilities, reinforcing Cipla's commitment to comprehensive respiratory care through its flagship centres in Mumbai and Delhi.

About Cipla

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ markets. Cipla is ranked 3rd largest in pharma in India (IQVIA MAT Dec'25), 2nd Largest in the pharma prescription market in South Africa (IQVIA MAT Nov'25), and 3rd largest by prescription in the US Gx (Repulses + MDI) products (IQVIA MAT Dec'25). For over nine decades, making a difference to patients has inspired every aspect of Cipla's work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility, and affordability to the centre of the HIV movement. A responsible corporate citizen, Cipla's humanitarian approach to healthcare in pursuit of its purpose of 'Caring for Life' and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers, and all stakeholders. For more, please visit www.cipla.com, or click on [Twitter](#), [Facebook](#), [LinkedIn](#). To learn more about the diagnostics and wellness services offered at Breathefree Lung Wellness Center (BLWC), visit www.ciplablwc.com

Media Contacts:

Corporate Communications

Heena Kanal

E-Mail: CorpComm@cipla.com

Investor Relations

Diksha Maheshwari

E-Mail: Investor.Relations@cipla.com